Last Updated: September 24, 2026

Details for Patent: 11,931,377


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,931,377 protect, and when does it expire?

Patent 11,931,377 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-five patent family members in six countries.

Summary for Patent: 11,931,377
Title:Methods of administering inhaled nitric oxide gas
Abstract:The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.
Inventor(s):James S. Baldassarre
Assignee: Mallinckrodt Hospital Products IP Unlimited Co , Mallinckrodt Pharma IP Trading DAC , Therakos Inc , Mallinckrodt Critical Care Finance Inc
Application Number:US16/378,361
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 11,931,377

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mallinckrodt Ireland INOMAX nitric oxide GAS;INHALATION 020845-004 Jan 17, 2023 RX Yes Yes 11,931,377 ⤷  Start Trial Y Y A METHOD FOR TREATING A PEDIATRIC PATIENT WHO IS EXPERIENCING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION RESULTING IN OXYGEN DESATURATION, WHEREIN THE PATIENT IS NOT DEPENDENT ON RIGHT-TO-LEFT SHUNTING OF BLOOD ⤷  Start Trial
Mallinckrodt Ireland INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 AA RX Yes Yes 11,931,377*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,931,377

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009202685 ⤷  Start Trial
Australia 2010202422 ⤷  Start Trial
Australia 2010206032 ⤷  Start Trial
Australia 2012201382 ⤷  Start Trial
Australia 2015100638 ⤷  Start Trial
Australia 2015100783 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.